Literature DB >> 8627795

Adenovirus-mediated expression of ribozymes in mice.

A Lieber1, M A Kay.   

Abstract

Ribozymes are a new pharmaceutical class of reagents that offer potential in treating a number of different medical disorders, including infectious diseases and cancer. As a first step towards using ribozymes for the treatment of liver disorders such as viral hepatitis, adenovirus vectors that contain a ribozyme expression cassette under the control of different promoters directed against human growth hormone (hGH) were constructed and infused into transgenic mice that produce hGH from the gastrointestinal tract and liver. Adenovirus-mediated transfer of expressed ribozymes resulted in up to a 96% reduction of hepatic hGH mRNA over a period of several weeks in the transgenic mouse model. Furthermore, the concentration of ribozyme RNA correlated with the degree of hGH mRNA reduction. This study clearly demonstrates that ribozymes can function during the period of expression in an intact organ after somatic gene transfer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627795      PMCID: PMC190178     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  High level gene expression in mammalian cells by a nuclear T7-phase RNA polymerase.

Authors:  A Lieber; U Kiessling; M Strauss
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

2.  Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library.

Authors:  A Lieber; M Strauss
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

3.  Assessment of recombinant adenoviral vectors for hepatic gene therapy.

Authors:  Q Li; M A Kay; M Finegold; L D Stratford-Perricaudet; S L Woo
Journal:  Hum Gene Ther       Date:  1993-08       Impact factor: 5.695

Review 4.  Antiviral and anticancer ribozymes.

Authors:  E Poeschla; F Wong-Staal
Journal:  Curr Opin Oncol       Date:  1994-11       Impact factor: 3.645

Review 5.  Gene therapy for metabolic disorders.

Authors:  M A Kay; S L Woo
Journal:  Trends Genet       Date:  1994-07       Impact factor: 11.639

6.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

Review 7.  Development of ribozymes for gene therapy.

Authors:  S M Sullivan
Journal:  J Invest Dermatol       Date:  1994-11       Impact factor: 8.551

8.  Cloning of the herpes simplex virus ICP4 gene in an adenovirus vector: effects on adenovirus gene expression and replication.

Authors:  R Spessot; K Inchley; T M Hupel; S Bacchetti
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

9.  Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme.

Authors:  S Larsson; G Hotchkiss; M Andäng; T Nyholm; J Inzunza; I Jansson; L Ahrlund-Richter
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

10.  Use of transgenic mice to map cis-acting elements in the liver fatty acid-binding protein gene (Fabpl) that regulate its cell lineage-specific, differentiation-dependent, and spatial patterns of expression in the gut epithelium and in the liver acinus.

Authors:  T C Simon; K A Roth; J I Gordon
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

View more
  15 in total

1.  Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats.

Authors:  D S Steinwaerder; C A Carlson; A Lieber
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Adenovirus-mediated expression of a ribozyme to c-myb mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo.

Authors:  D G Macejak; H Lin; S Webb; J Chase; K Jensen; T C Jarvis; J M Leiden; L Couture
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 3.  Perspectives for the treatment of infections with Flaviviridae.

Authors:  P Leyssen; E De Clercq; J Neyts
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  A selection system for identifying accessible sites in target RNAs.

Authors:  W H Pan; H F Devlin; C Kelley; H C Isom; G A Clawson
Journal:  RNA       Date:  2001-04       Impact factor: 4.942

5.  Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.

Authors:  M M LaVail; D Yasumura; M T Matthes; K A Drenser; J G Flannery; A S Lewin; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

6.  Disruption of the c/ebp alpha gene in adult mouse liver.

Authors:  Y H Lee; B Sauer; P F Johnson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

7.  Essential role of mitochondrially encoded large rRNA for germ-line formation in Drosophila embryos.

Authors:  T Iida; S Kobayashi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

Review 8.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

9.  A ribozyme-mediated, gene "knockdown" strategy for the identification of gene function in zebrafish.

Authors:  Y Xie; X Chen; T E Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

Review 10.  Ribozymes. Their functions and strategies for their use.

Authors:  S A Gibson; E J Shillitoe
Journal:  Mol Biotechnol       Date:  1997-04       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.